Contemporary Biomarker Testing Rates in Both Early and Advanced NSCLC: Results From the MYLUNG Pragmatic Study

News
Video

Related Videos
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Sundar Jagannath, MBBS
Nikhil Gopal, MD, assistant professor, urology, College of Medicine, Memphis Department of Urology, The University of Tennessee Health Science Center
Somedeb Ball, MBBS
Lauren E. Nye, MD
Jonathan E. Rosenberg, MD
Emil Lou, MD, PhD, FACP
Jean L. Koff, MD, MS
Related Content
Hope S. Rugo, MD

Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer

May 16th 2024
Article
D. Ross Camidge, MD, PhD; İlker Arslan, MD, United States medical head, TDR Lung, AstraZeneca

Camidge and Arslan Calculate the “Impact Factor” of a Career in Medicine

May 16th 2024
Podcast
Mafalda Oliveira, MD, PhD

Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer

May 16th 2024
Article
Jubilee Brown, MD, professor, director, Gynecologic Oncology, Atrium Health Levine Cancer Institute

Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer

May 13th 2024
Podcast
Komal Jhaveri, MD, FACP

Dato-DXd Reduces High-Grade TRAEs vs Chemo in Pretreated, HR+/HER2– Advanced Breast Cancer

May 16th 2024
Article
FDA

FDA to Hold End-of-Phase 2 Meeting for Botensilimab Plus Balstilimab in R/R mCRC

May 16th 2024
Article